Valuation: Alkermes plc

Market Cap 9.18B 8.04B 7.42B 6.93B 13.04B 868B 13.34B 89.3B 34.47B 428B 34.48B 33.72B 1,487B P/E 2026 *
-145x
P/E 2027 * 92.6x
Enterprise Value 10.14B 8.88B 8.2B 7.66B 14.41B 959B 14.74B 98.65B 38.08B 473B 38.09B 37.25B 1,642B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 5.22x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-4.63%
1 week+14.15%
Current month+24.51%
1 month+24.51%
3 months+74.23%
6 months+87.54%
Current year+87.74%
1 week 45.47
Extreme 45.47
55.28
1 month 40.62
Extreme 40.62
55.28
Current year 27
Extreme 27
55.28
1 year 25.16
Extreme 25.165
55.28
3 years 22.01
Extreme 22.01
55.28
5 years 21.24
Extreme 21.24
55.28
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
06-12Sell

Director

-2,000 0.0012%
06-04Sell

Compliance Officer

-2,034 0.0012%
06-01Fiscal year

Chief Technology Officer

19,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
-4.63%+14.15%+83.61%+67.67% 9.18B
+0.94%+8.20%-4.77%+1.97% 46.2B
+5.79%+16.17%+423.57%+634.63% 38.71B
+1.12%+15.18%+22.65%-12.71% 31.9B
+3.61%+6.69%+19.80%+62.38% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
+1.13%+15.66% - - 16.2B
+1.45%+17.35%+70.37%+127.60% 15.05B
-1.13%+9.05%+12.03%+18.95% 13.74B
-0.60%+6.32%+104.23%+96.28% 13.42B
Average +1.51%+11.78%+83.24%+114.68% 23.93B
Weighted average by Cap. +2.31%+10.55%+95.59%+139.53%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.46B 1.37B 2.57B 171B 2.63B 17.62B 6.8B 84.49B 6.8B 6.65B 293B 1.89B 1.66B 1.53B 1.43B 2.69B 179B 2.75B 18.4B 7.1B 88.24B 7.11B 6.95B 306B
Net income -62.35M -54.6M -50.4M -47.07M -88.6M -5.9B -90.62M -607M -234M -2.91B -234M -229M -10.1B 108M 94.66M 87.39M 81.6M 154M 10.22B 157M 1.05B 406M 5.04B 406M 397M 17.51B
Net Debt 961M 842M 777M 726M 1.37B 90.88B 1.4B 9.35B 3.61B 44.83B 3.61B 3.53B 156B 702M 614M 567M 530M 997M 66.32B 1.02B 6.82B 2.63B 32.72B 2.63B 2.58B 114B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
29/06/26 $52.53 -4.63% 2,938,438
26/06/26 $55.08 +4.26% 7,563,601
25/06/26 $52.83 +4.72% 3,249,672
24/06/26 $50.45 +4.95% 3,726,629
23/06/26 $48.07 +4.45% 2,451,924
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
55.08USD
Average target price
49.44USD
Spread / Average Target
-10.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock